RJA
RPRX icon

Ross\Johnson & Associates’s Royalty Pharma RPRX Stock Holding History

Ross\Johnson & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77
Closed -$2.4K – 321
2025
Q1 		$2.4K Buy
+77
New +$2.44K 0.04% 150

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Ross\Johnson & Associates's RPRX Position: Q2 2025 in Review

Ross\Johnson & Associates sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 77 shares — an estimated $2.4K sold.

Ross\Johnson & Associates first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $2.4K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Ross\Johnson & Associates reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Ross\Johnson & Associates sold 77 Royalty Pharma shares in Q2 2025, an estimated $2.4K.
  • Ross\Johnson & Associates first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
  • Ross\Johnson & Associates's Royalty Pharma position peaked at $2.4K in Q1 2025.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Ross\Johnson & Associates's 13F filing for Q2 2025, filed 15 Aug 2025.